Sunesis Pharmaceuticals (SNSS) Reports Strong Q1 Results
Tweet
Share
E-mailGet Alerts SNSS Hot Sheet
Join SI Premium – FREE
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported Q1 EPS of $0.04, $0.18 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $4 million, versus $13 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- Yiren Digital Ltd. (YRD) Reports Q2 Loss of RMB5.11
- Jefferies Financial stock slips 3% as Fixed Income, Asset Management revenues fall
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
